Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine ...

20 August 2026 · By · Wire by Fusion42

Published

20 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 20 August 2026 · Fusion42 review

The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test, advancing precision medicine for Alzheimer's disease diagnosis by providing a less invasive and more accessible biomarker test option.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You face new opportunities as blood-based Alzheimer's testing gains regulatory approval, reducing barriers to market and patient access. Adjust your clinical plans now to integrate more scalable and less invasive diagnostic methods.

◆ Coverage

3 sources · 20 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-clearancealzheimersprecision-medicineblood-testdiagnostics